A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease-Reference-Cited by-同舟云学术

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease

Published:2017-05 Issue:3 Volume:2 Page:451-460
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Perrone Ronald D.,Mouksassi Mohamad-Samer,Romero Klaus,Czerwiec Frank S.,Chapman Arlene B.,Gitomer Berenice Y.,Torres Vicente E.,Miskulin Dana C.,Broadbent Steve,Marier Jean F.

Publisher

Elsevier BV

Subject

Nephrology

Reference24 articles.

1. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities;Torres;J Intern Med,2007

2. Polycystic kidney disease;Wilson;N Engl J Med,2004

3. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease;Chapman;Clin J Am Soc Nephrol,2012

4. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials;Irazabal;J Am Soc Nephrol,2015

5. Determinants of renal volume in autosomal-dominant polycystic kidney disease;Grantham;Kidney Int,2008

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Model-informed Drug Development (MIDD) in Regulatory Submissions for Drug Approval in Japan;2024-07-18

2. Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis;Kidney360;2024-06-10

3. Model‐Informed Approaches and Innovative Clinical Trial Design for Adeno‐Associated Viral Vector‐Based Gene Therapy Product Development: A White Paper;Clinical Pharmacology & Therapeutics;2023-06-29

4. Polycystic Kidney Disease Drug Development: A Conference Report;Kidney Medicine;2023-03

5. Atypical Polycystic Kidney Disease as defined by Imaging;Scientific Reports;2023-02-20